Pharming Group (NASDAQ:PHAR) Shares Gap Down – Time to Sell?

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) gapped down before the market opened on Tuesday . The stock had previously closed at $17.55, but opened at $16.60. Pharming Group shares last traded at $16.2710, with a volume of 28,703 shares traded.

Wall Street Analyst Weigh In

PHAR has been the subject of several analyst reports. Zacks Research raised shares of Pharming Group from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. Weiss Ratings lowered Pharming Group from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $30.00.

Pharming Group Trading Down 6.8%

The company’s 50 day moving average price is $14.36 and its 200 day moving average price is $12.12. The firm has a market cap of $1.12 billion, a PE ratio of -1,633.37 and a beta of 0.03. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.16 and a quick ratio of 2.39.

Pharming Group (NASDAQ:PHAR) last released its earnings results on Thursday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05. The company had revenue of $97.30 million for the quarter, compared to analyst estimates of $98.22 million. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. Pharming Group has set its FY 2025 guidance at EPS. As a group, analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current fiscal year.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its holdings in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) by 8.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,147 shares of the company’s stock after buying an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.08% of Pharming Group worth $557,000 as of its most recent SEC filing. 0.03% of the stock is currently owned by institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.